Clinica Baviera, SA (ES:CBAV)
BME:CBAV
Want to see ES:CBAV full AI Analyst Report?
CBAV Stock Chart & Stats
€47.30
€0.20(0.61%)
At close: 4:00 PM EST
€47.30
€0.20(0.61%)
Day’s Range― - ―
52-Week Range€36.90 - €58.00
Previous CloseN/A
Volume285.00
Average Volume (3M)2.20K
Market Cap
€909.73M
Enterprise Value€912.67M
Total Cash (Recent Filing)€50.32M
Total Debt (Recent Filing)€69.16M
Price to Earnings (P/E)15.3
Beta0.58
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.31%
Share Statistics
EPS (TTM)2.57
Shares Outstanding16,307,580
10 Day Avg. Volume2,444
30 Day Avg. Volume2,202
Financial Highlights & Ratios
PEG Ratio4.33
Price to Book (P/B)7.52
Price to Sales (P/S)2.74
P/FCF Ratio17.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.86
Revenue Forecast (FY)€325.40M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthMulti-year top-line growth (2021–2025) indicates durable demand for ophthalmology services and successful clinic throughput expansion. A steady revenue base supports reinvestment in clinics and technology, underpins predictable margins and reduces reliance on one-off procedure spikes.
Strong Operating Cash GenerationConsistent operating cash flow above reported earnings signals high earnings quality and internal funding capacity. This strengthens the company’s ability to fund capex, service debt, and sustain investments in equipment and training without overreliance on external financing.
Improving Balance Sheet And ReturnsRising equity and improved leverage through 2023–2024, along with strong returns on shareholders' capital, enhance financial resilience and provide capacity for strategic investments or acquisitions. This supports long-term competitive positioning and operational flexibility.
Bears Say
Rising Debt TrendHigher debt levels into 2024–2025 reduce financial optionality and raise interest and refinancing risk. If revenue or free cash flow weakens, rising leverage could constrain capital allocation, limit M&A or capex, and pressure margins via higher financing costs.
Volatile Free Cash FlowSharp FCF declines in 2023 and 2025 signal variability in investment needs or working capital that can impair the company’s ability to service debt, fund growth, or return capital. Persistent FCF volatility increases reliance on external funding during downturns.
Margin Transparency / One-off ItemsUnusually high 2024 gross profit and missing 2025 margin detail suggest possible one-offs or reporting noise. This undermines confidence in sustainably achievable margins and complicates forecasting and capital planning for investors and management.
Clinica Baviera News
CBAV FAQ
What was Clinica Baviera, SA’s price range in the past 12 months?
Clinica Baviera, SA lowest stock price was €36.90 and its highest was €58.00 in the past 12 months.
What is Clinica Baviera, SA’s market cap?
Clinica Baviera, SA’s market cap is €909.73M.
When is Clinica Baviera, SA’s upcoming earnings report date?
Clinica Baviera, SA’s upcoming earnings report date is Jul 28, 2026 which is in 78 days.
How were Clinica Baviera, SA’s earnings last quarter?
Clinica Baviera, SA released its earnings results on Mar 04, 2026. The company reported €0.813 earnings per share for the quarter, beating the consensus estimate of N/A by €0.813.
Is Clinica Baviera, SA overvalued?
According to Wall Street analysts Clinica Baviera, SA’s price is currently Overvalued.
Does Clinica Baviera, SA pay dividends?
Clinica Baviera, SA pays a Annually dividend of €1.57 which represents an annual dividend yield of 3.31%. See more information on Clinica Baviera, SA dividends here
What is Clinica Baviera, SA’s EPS estimate?
Clinica Baviera, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera, SA have?
Clinica Baviera, SA has 16,307,580 shares outstanding.
What happened to Clinica Baviera, SA’s price movement after its last earnings report?
Clinica Baviera, SA reported an EPS of €0.813 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.789%.
Which hedge fund is a major shareholder of Clinica Baviera, SA?
Currently, no hedge funds are holding shares in ES:CBAV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinica Baviera, SA
Clinica Baviera (CBAV) is a leading provider of ophthalmological services in Spain and several other countries, specializing in vision correction procedures such as LASIK and cataract surgery. The clinic operates a network of medical centers equipped with advanced technology and staffed by highly trained professionals to deliver quality eye care. In addition to surgical interventions, Clinica Baviera offers comprehensive eye examinations, diagnostic services, and post-operative care, focusing on improving patients' quality of life through enhanced vision.
Technical Analysis
Options Prices
Currently, No data available
---